Time to and factors associated with initiation of biological therapy in patients with rheumatoid arthritis in Colombia

Machado-Alba, Jorge E; García-Betancur, Santiago; Calvo-Torres, Luis F; Medina-Morales, Diego Alejandro; Bañol-Giraldo, Alejandra M.
Rev. colomb. reumatol ; 25(1): 3-8, Jan.-Mar. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-960243

Documentos relacionados

  1. The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients.
  2. Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study.
  3. [Biological treatment of psoriatic arthritis].
  4. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study.
  5. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
  6. Long-term survival of biological therapy in psoriatic arthritis: 18-year analysis of a cohort in a tertiary hospital.
  7. Clinical phenotype with high risk for initiation of biologic therapy in rheumatoid arthritis: a data-driven cluster analysis.
  8. Adherence to biological therapies in patients with rheumatoid arthritis: a retrospective cohort study.
  9. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.
  10. HLA-Cw6 allele and biologic therapy are protective factors against liver fibrosis in psoriatic arthritis patients.